This review examines the landscape of RHAMM-targeted immunotherapies, from peptide vaccines to dendritic cell (DC)-based treatments, evaluating their efficacy and the challenges encountered in leveraging RHAMM for cancer immunotherapy. This evidence concerns the gene HMMR and cancer.